Sanofi Bags EU Approvals But Fumes At Regulator
Green Lights For Nexviadyme And Xenpozyme
Executive Summary
Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.
You may also be interested in...
EU’s ‘Significant Benefit’ Metric For Orphan Drugs Still A Thorn In Industry’s Side
Ipsen’s Bylvay is one of six medicines that the European Medicines Agency has said should be stripped of their orphan drug designation over the last three years, leading the company to criticize the agency’s approach to “significant benefit” assessments.
Sanofi Files New Pompe Hope Avalglucosidase Alfa In EU
The French drugmaker is looking to consolidate its dominance of the Pompe disease area by filing its successor to Myozyme in Europe, but Amicus Therapeutics' potential rival AT-GAA is on the horizon.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.